Compare LINK & MAIA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | LINK | MAIA |
|---|---|---|
| Founded | 1984 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 59.5M | 49.3M |
| IPO Year | N/A | 2022 |
| Metric | LINK | MAIA |
|---|---|---|
| Price | $3.18 | $1.97 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $8.67 | N/A |
| AVG Volume (30 Days) | 34.4K | ★ 1.3M |
| Earning Date | 03-26-2026 | 03-20-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $12,023,000.00 | N/A |
| Revenue This Year | $8.30 | N/A |
| Revenue Next Year | $34.68 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $2.76 | $0.87 |
| 52 Week High | $10.10 | $3.19 |
| Indicator | LINK | MAIA |
|---|---|---|
| Relative Strength Index (RSI) | N/A | N/A |
| Support Level | N/A | N/A |
| Resistance Level | N/A | N/A |
| Average True Range (ATR) | 0.00 | 0.00 |
| MACD | 0.00 | 0.00 |
| Stochastic Oscillator | 0.00 | 0.00 |
Interlink Electronics Inc is a sensor and printed electronics company operating in two principal sensor technology divisions: force/touch sensors, and gas and environmental sensors. It designs, develops, manufactures and sells a range of force-sensing and gas-sensing technologies that incorporate its proprietary materials technology, firmware and software into a portfolio of standard sensor-based products and custom sensor system solutions. Its force-sensing products and solutions include sensor components, subassemblies, modules products that support effective, efficient cursor control and novel three-dimensional user inputs. Its Human Machine Interface technology platforms are deployed in a wide range of markets including consumer electronics, automotive, industrial, and medical.
MAIA Biotechnology Inc is a clinical-stage biopharmaceutical company developing targeted immunotherapies for cancer. THIO (6-thio-dG or 6-thio-2 '-deoxyguanosine), its lead asset, is an investigational dual mechanism of action drug candidate incorporating telomere targeting and immunogenicity. Patients with advanced NSCLC will be treated first with THIO followed a few days later by the immune checkpoint inhibitor Libtayo (cemiplimab), manufactured and commercialized by Regeneron.